PD-L1 expression in GI cancer and Immune checkpoint inhibitor

2019 Fiscal Year Final Research Report

• Project/Area Number: 16K10511
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Fukushima Medical University
• Principal Investigator: Kono Koji 福島県立医科大学, 医学部, 教授 (40283204)
• Co-Investigator(Kenkyū-buntansha): 中島 隆宏 福島県立医科大学, 医学部, 博士研究員 (90567447)
• Project Period (FY): 2016-04-01 – 2020-03-31
• Keywords: 免疫チェックポイント阻害 / 消化器癌 / Nivolmab

Outline of Final Research Achievements

(I)PD-L1 is upregulated by IFN-g through JAK-STAT pathway in GI-tract cancer.(II)There is a positive correlation between EMT status and PD-L1 expression in GI tract cancer.(III)microRNA from tumor microenvironment can down-regulate PD-L1 expression in colon cancer

Free Research Field

消化器外科学

Academic Significance and Societal Importance of the Research Achievements

消化器癌におけるPD-L1の発現調節機構を解明することで、免疫チェックポイント阻害剤の効果増強、ResponderのPrediction、Non-responderの機序解明に寄与できる。